Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2009 2
2010 1
2011 2
2012 1
2014 3
2015 2
2016 1
2017 1
2018 1
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Pyk2 promotes tumor progression in multiple myeloma.
Zhang Y, Moschetta M, Huynh D, Tai YT, Zhang Y, Zhang W, Mishima Y, Ring JE, Tam WF, Xu Q, Maiso P, Reagan M, Sahin I, Sacco A, Manier S, Aljawai Y, Glavey S, Munshi NC, Anderson KC, Pachter J, Roccaro AM, Ghobrial IM. Zhang Y, et al. Among authors: xu q. Blood. 2014 Oct 23;124(17):2675-86. doi: 10.1182/blood-2014-03-563981. Epub 2014 Sep 12. Blood. 2014. PMID: 25217697 Free PMC article.
Inhibition of FAK kinase activity preferentially targets cancer stem cells.
Kolev VN, Tam WF, Wright QG, McDermott SP, Vidal CM, Shapiro IM, Xu Q, Wicha MS, Pachter JA, Weaver DT. Kolev VN, et al. Among authors: xu q. Oncotarget. 2017 Jun 16;8(31):51733-51747. doi: 10.18632/oncotarget.18517. eCollection 2017 Aug 1. Oncotarget. 2017. PMID: 28881682 Free PMC article.
In vitro and in vivo anticancer activity of (+)-spongistatin 1.
Xu Q, Huang KC, Tendyke K, Marsh J, Liu J, Qiu D, Littlefield BA, Nomoto K, Atasoylu O, Risatti CA, Sperry JB, Smith AB 3rd. Xu Q, et al. Anticancer Res. 2011 Sep;31(9):2773-9. Anticancer Res. 2011. PMID: 21868519 Free PMC article.
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Caligiuri M, Williams GL, Castro J, Battalagine L, Wilker E, Yao L, Schiller S, Toms A, Li P, Pardo E, Graves B, Azofeifa J, Chicas A, Herbertz T, Lai M, Basken J, Wood KW, Xu Q, Guichard SM. Caligiuri M, et al. Among authors: xu q. Target Oncol. 2023 Mar;18(2):269-285. doi: 10.1007/s11523-023-00949-7. Epub 2023 Feb 24. Target Oncol. 2023. PMID: 36826464 Free PMC article.
PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.
Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, Ricono J, Weaver DT, Padval MV, Pachter JA, Xu Q. Kolev VN, et al. Among authors: xu q. Cancer Res. 2015 Jan 15;75(2):446-55. doi: 10.1158/0008-5472.CAN-14-1223. Epub 2014 Nov 28. Cancer Res. 2015. PMID: 25432176
Total synthesis of ipomoeassin F.
Postema MH, TenDyke K, Cutter J, Kuznetsov G, Xu Q. Postema MH, et al. Among authors: xu q. Org Lett. 2009 Mar 19;11(6):1417-20. doi: 10.1021/ol900086b. Org Lett. 2009. PMID: 19228042
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, Xu Q, Testa JR, Pachter JA. Shapiro IM, et al. Among authors: xu q. Sci Transl Med. 2014 May 21;6(237):237ra68. doi: 10.1126/scitranslmed.3008639. Sci Transl Med. 2014. PMID: 24848258 Free PMC article.
17 results